Hypertension, also known as high blood pressure, is a prevalent medical condition that affects millions of people worldwide. It is often...

Zolmitriptan is a drug developed to treat migraines and cluster headaches. This medication works by narrowing blood vessels in the brain,...

Zonisamide is a medication used to treat epilepsy and Parkinson's disease. It works by reducing abnormal electrical activity in the...

Cardiovascular diseases remain the leading cause of death worldwide, with heart failure being one of the most common and lethal. Heart...

Zolazepam is a drug that has been developed and used in veterinary medicine for many years. It is a type of benzodiazepine and is...

Zotepine: A Comprehensive Review of Research and Development Antipsychotic medications are commonly prescribed to individuals with...

Elixir Medical, a California-based company, may have struck gold in the realm of vascular restoration with their innovative device, the...

Zopolrestat, a small molecule drug popularly known by its synonym, Xedia, has recently attracted significant attention in the medical...

1.1 A Brief Overview Established in 2007, PatSnap has emerged as a leading player in the technology and innovation information services...

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX), commonly referred to as "Calliditas," has released preliminary data...

1 Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure Lexicon Pharmaceuticals announced that the...

1 U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent...

1 Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure Lexicon Pharmaceuticals announced that the...

1. U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent...

1. U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer announced...

1 Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI®...

1 First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately...

1. NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with...

1. Astra Zeneca's Selumetini Approved for the Neurofibromatosis Type 1 and Plexiform Neurofibromas in China AstraZeneca announced...

1 FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with...